As a specialized consultancy, tkc suisse supports biotech companies, innovative drug hunters and investors in their quest to develop future medicines and helps clients navigate the complex landscape of drug discovery and development. Leveraging their expertise in model-informed drug development, tkc suisse assists to define the drug development path with increased chances of success for novel therapies. Their services encompass predictions of efficacy and safety profiles in patients with PKPD models integrating data across various studies, including in vitro, preclinical, and clinical data. Additionally, tkc suisse facilitates a successful transition from discovery to development, design of effective proof-of-concept studies and the selection of optimal dosing regimen with clinical trial simulations, preventing avoidable failures due to inadequate dosing decisions and reducing the risk of late-stage failures or registration delays.

Our services

For Biotech and innovative drug hunters

Model-informed Drug Discovery

  • Target and/or modality assessment: Is the target druggable? What is the optimal modality? Can we reach efficacious exposure at the site of action?

  • Competitive benchmarking: How does the novel asset compare to competitor molecules? What is the ideal target product profile and favorable drug properties for a competitive advantage?

Model-informed Drug Development

  • Designing and analyzing informative PK and PKPD studies integrating biomarker information

  • Building translational PK and PKPD models and providing regulatory documentation

  • Predicting human PK and PKPD to guide dose selection in early clinical studies

  • Supporting regulatory IND/CTA applications and strengthen

  • Designing toxicology studies to ensure sufficient exposure multiples in clinical studies

  • Leveraging translational modeling and simulation to design more effective clinical proof-of-concept studies

  • clinical trial simulation to select appropriate dosage before initiating clinical studies

  • design of dose selection studies

For Investors

For investors interested in innovative therapies, tkc suisse provides valuable support in evaluating the chances of success for novel assets. Their model-informed approaches assist investors by:

  • Assessing the feasibility of therapeutic concepts

  • Supporting due diligence processes with expert analysis of quantitative pharmacology, DMPK, and PKPD aspects

  • Identifying potential show-stoppers and proposing de-risking activities

  • Defining critical experiments and designing effective proof-of-concept studies for milestone-based Go/NoGo decisions

  • Guiding rational drug design and compound selection

  • Predicting optimal dosage and dosing regimens to achieve therapeutic effects while minimizing safety concerns